A Day Of Reckoning for Aging Facilities: Is It Time To Invest In Change?
This article was originally published in Scrip
Executive Summary
With its acquisition of Hospira, Pfizer joins those struggling to eke out a profit from aging sterile injectables facilities without shutting them down for badly needed upgrades. Meanwhile, flexible, modular next-generation facilities are looming. Bowman Cox, editor of "The Gold Sheet" looks at the possibilities for the industry's golden oldies.
You may also be interested in...
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.
US FDA Seeks More Power To Confront ‘Shadow’ Factory Challenges
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find manufacturer of contaminated eye drops that disappeared.